Association between glucagon-like peptide-1 receptor agonists and thyroid carcinoma; a systematic review and meta-analysis of observational studies
Authors:
- Mojtaba LotfiMLMojtaba Lotfi
- Mahboobeh AkhondiMAMahboobeh Akhondi
- Mehrangiz GhafariMGMehrangiz Ghafari
- Mahmoud Dehghani-GhorbiMDMahmoud Dehghani-Ghorbi
- Mehrnaz Nazari RadMRMehrnaz Nazari Rad
- Maedeh Seifollahi MarbiniMMMaedeh Seifollahi Marbini
- Mahsa EbrahimiMEMahsa Ebrahimi
- Seyed Amir SheikholeslamiSSSeyed Amir Sheikholeslami
- Sajad Ataei AzimiSASajad Ataei Azimi
Open Access
- 1 June 2025
- journal article
- review article
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13 (1) , e13293
Abstract
Introduction: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are drugs administered to treat type 2 diabetes mellitus; however, their relationship with thyroid cancer is still unclear. Hence, the present study aimed to examine the association between the use of GLP1-RA and thyroid carcinoma. Materials and Methods: Databases searched—including Web of Science, Cochrane, Scopus, ProQuest, PubMed, Embase, and Google Scholar—were searched without a time limit until May 1, 2025. Data were entered into SPSS 19 and analyzed using STATA 14. Tests with P values less than 0.05 were considered statistically significant (P < 0.05). Results: The relationship between GLP1-RA and thyroid carcinoma based on hazard ratio (HR: 1.14, 95% CI: 0.86, 1.51) and incidence rate ratio (IRR: 1.32, 95% CI: 0.79, 2.20) was statistically insignificant. However, according to odds ratio (OR), use of GLP1-RA increased the risk of thyroid cancer (OR: 1.46, 95% CI: 1.23, 1.74). Furthermore, the association between GLP1-RA and medullary thyroid carcinoma was insignificant (HR: 1.51, 95% CI: 0.90, 2.54). The relationship between GLP1-RA and thyroid carcinoma among women (HR: 1.01, 95% CI: 0.69, 1.47), men (HR: 0.72, 95% CI: 0.33, 1.57), individuals aged 50 to 59 (HR: 1.30, 95% CI: 0.96, 1.75), 60 to 69 (HR: 0.95, 95% CI: 0.65, 1.38), in China (HR: 1.26, 95% CI: 0.91, 1.76), France (HR: 3.43, 95% CI: 1.30, 9.04), and Korea (HR: 1.05, 95% CI: 0.76, 1.46) was statistically insignificant. However, in the USA (HR: 1.44, 95% CI: 1.22, 1.71), GLP1-RA administration increased the risk of thyroid neoplasm. Conclusion: Generally, the relationship between the GLP1-RA use in patients with type 2 diabetes mellitus and the risk of thyroid carcinoma was insignificant. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251051827) and Research Registry (reviewregistry1993) websites.Keywords
This publication has 37 references indexed in Scilit:
- GLP-1RA Use and Thyroid Cancer RiskJAMA Otolaryngology–Head & Neck Surgery, 2025
- Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysisInternational Urology and Nephrology, 2024
- Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trialsPharmacological Research, 2024
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsThe Lancet Diabetes & Endocrinology, 2021
- Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational StudiesDiabetes Therapy, 2021
- GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trialsEndocrine, 2019
- Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysisScientific Reports, 2019
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Biological actions and therapeutic potential of the glucagon-like peptidesGastroenterology, 2002